Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Gastroenterology
•
General Hepatology
How you do approach treatment for a patient with active seropositive RA (+RF/+CCP) who is receiving treatment for Hepatitis C?
Related Questions
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Does hepatitis B vaccination reduce the risk of HBV reactivation associated with immunosuppressive therapy?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
How do you choose between resmetirom and semaglutide in the treatment of MASH?
